Dr. Haibo Qiu 邱海波
Chief Physician
Department of Gastric Surgery, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of gastrointestinal tumors, including laparoscopic and robotic minimally invasive surgery for gastric cancer and gastrointestinal stromal tumors (GIST). Expertise includes open surgery, targeted therapy for GIST, and conversion therapy for gastric cancer.
Dr. Qiu holds a medical doctorate and completed joint doctoral training at Harvard Medical School. A professorial supervisor, Dr. Qiu has published over 40 SCI papers and presented at ASCO 2024 and ESMO 2024. Research is supported by the National Natural Science Foundation. Dr. Qiu received the CSCO 35 under 35 award.
Professional roles
- Vice Chair, Gastrointestinal Stromal Tumor Youth Committee, China Anti-Cancer Association
- Committee Member, CSCO Gastrointestinal Stromal Tumor Expert Committee
- Deputy Leader, CSCO Translation Group
- Young Editorial Board Member, Journal of Oncology
Name order: in Chinese the family name comes first (Qiu Haibo). Papers usually list the name as Haibo Qiu or Qiu H.
Selected publications
90 papers on PubMed matched by name and affiliation; 22 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Vis Exp, 2026 (senior author): A Modified Approach in Robotic Gastrectomy for Gastric Cancer. PubMed 42980193
- Cancer Invest, 2026 (senior author): Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting System. PubMed 42402704
- Cancer Med, 2026 (senior author): Comparative Effectiveness and Modality-Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer. PubMed 41674205
- Signal Transduct Target Ther, 2025 (first author): Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research. PubMed 41184234
- Cancer Commun (Lond), 2025 (senior author): Cancer situation in China: an analysis based on the global epidemiological data released in 2024. PubMed 39659114
- Oncol Lett, 2024 (senior author): Radiofrequency ablation vs. hepatectomy for liver metastases from gastrointestinal stromal tumors. PubMed 38362234
- Cancer Commun (Lond), 2023 (senior author): Physical activity and cancer risk: a dose-response analysis for the Global Burden of Disease Study 2019. PubMed 37743572
- Biomolecules, 2023 (senior author): TRIM6: An Upregulated Biomarker with Prognostic Significance and Immune Correlations in Gliomas. PubMed 37759698
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion